Placeholder Banner

Positive Results in Plague Study

September 29, 2009
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced results from a primate study involving the oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague. The study tested Restanza's protective efficacy at various doses up to 64 mg/kg, where nine out of ten animals in the study that received a 14-day course of Restanza initiated within 24 hours after exposure to a lethal dose of plague survived while only one out of ten of the animals that received placebo survived. Known as the "black death," a plague epidemic decimated Europe in the Middle Ages, killed more than 10 million people in India a century ago and today mainly affects people who come into contact with infected rodents.

Read the release.